Introduction to Pooled Plasma Therapies
Pooled plasma therapies, such as those treated with solvent/detergent (S/D), play a crucial role in the treatment of various life-threatening and rare diseases. These therapies are derived from human plasma and are essential for replacing deficient or dysfunctional proteins in the body.
Market Size and Growth
The global market for plasma-derived therapies, which includes pooled plasma products like Octaplas, is experiencing significant growth. In 2022, the plasma-derived therapy market was valued at over USD 16.8 billion and is projected to grow at a compound annual growth rate (CAGR) of 7.5% between 2023 and 2032[1].
By 2027, the plasma protein therapeutics market is expected to reach over USD 32 billion, growing at a CAGR of 7.3% from 2020[2]. Similarly, the global plasma-derived medicine market is estimated to be valued at USD 18.50 billion in 2024 and is expected to reach USD 30.12 billion by 2031, with a CAGR of 7.2% from 2024 to 2031[4].
Key Drivers of Market Growth
Several factors are driving the growth of the plasma-derived therapy market:
Increasing Prevalence of Rare Diseases
The rising prevalence of rare diseases such as primary immunodeficiency diseases, hemophilia, and idiopathic thrombocytopenic purpura (ITP) is a major driver. These conditions often lack alternative treatment options, making plasma-derived therapies indispensable[1][2][4].
Aging Population and New Drug Approvals
An aging population and the approval of new protein therapy drugs are also contributing to the market's expansion. As the population ages, the demand for treatments that address age-related health issues increases[2].
Cost Savings in Healthcare
Plasma-derived therapies offer significant cost savings compared to alternative treatments. For example, immunoglobulin therapy for primary immune deficiency can save $60,000 annually per patient, and albumin therapies can save hundreds of thousands in care costs for conditions like burn shock and trauma[2].
Product Categories and Applications
The plasma-derived therapy market is categorized into several product types:
Immunoglobulins
Immunoglobulins held 48.1% of the market share in 2022 and are used to treat primary immunodeficiency diseases and other conditions[1].
Coagulation Factors
Coagulation factors are crucial for treating bleeding disorders such as hemophilia. The hemophilia segment dominated the global market share, valued at USD 6.5 billion in 2022[1].
Albumin and Other Products
Albumin is used in various medical conditions, including liver disease, cardiac surgery, and liver transplantation. Other products include those used for plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)[3].
Regional Market Dynamics
North America
North America holds a significant market share, with over 52.2% of the business share in 2022. The presence of major industry players like Shire, CSL Behring, and Grifols, along with favorable regulatory environments, contributes to the region's dominance[1][4].
Europe
Europe has a well-developed plasma collection infrastructure, with countries like Germany and Austria leading in plasma collection. European companies are significant exporters of plasma-derived medicines, although they face increasing competition from U.S. players[4].
China
China is emerging as the fastest-growing regional market, driven by rapid economic growth, growing medical needs, and rising healthcare expenditures. The government's push for developing the domestic biologics industry has attracted significant investments from multinational companies[4].
Financial Performance of Key Players
Companies like Grifols are reporting solid financial performance in the plasma-derived therapy market. Grifols achieved an all-time high of EUR 6,592 million in total revenues in 2023, driven by strong demand for their key proteins and the recovery of plasma volumes[5].
Challenges and Opportunities
Supply and Demand Imbalances
The market faces challenges related to supply and demand imbalances. The projected growth in plasma demand, potentially reaching a 10-fold increase by 2040, necessitates the expansion of collection centers and donor programs to meet the rising demand[2].
Infrastructure Expansion
Expanding plasma collection infrastructure is crucial to meet the projected supply needs. Building additional community plasma centers and implementing donor programs can help drive the necessary increases in plasma supply[2].
Regulatory and Financial Considerations
Securing financing for costly new fractionation plants and navigating regulatory environments are also critical factors. The favorable regulatory environment in regions like North America attracts new players and supports market growth[4].
Cost Savings and Healthcare Impact
Plasma-derived therapies not only improve patient health outcomes but also reduce medical expenditures significantly. For instance:
"Plasma-based medicines also reduce healthcare costs by $60,000 per patient versus alternatives"[2].
This cost savings is a significant factor in the adoption and growth of these therapies.
Donor Compensation and Motivation
Donor compensation models, including per donation payments, frequent donor programs, lottery systems, and referral rewards, play a vital role in motivating consistent donations. Donors can earn substantial supplemental income, often through prepaid debit cards, which helps cover the operating costs of plasma collection centers[2].
Conclusion
The market for pooled plasma therapies, such as those treated with solvent/detergent, is poised for significant growth driven by increasing demand for treatments of rare diseases, an aging population, and new drug approvals. While challenges related to supply and demand imbalances exist, the expansion of plasma collection infrastructure and donor programs offers opportunities for sustainable growth.
Key Takeaways
- The plasma-derived therapy market is valued at over USD 16.8 billion in 2022 and is expected to grow at a CAGR of 7.5% until 2032.
- Increasing prevalence of rare diseases and an aging population are key drivers of market growth.
- North America and Europe are dominant regions, with China emerging as a fast-growing market.
- Plasma-derived therapies offer significant cost savings in healthcare.
- Expanding plasma collection infrastructure is crucial to meet rising demand.
FAQs
What is the projected growth rate of the plasma-derived therapy market?
The plasma-derived therapy market is projected to grow at a CAGR of 7.5% between 2023 and 2032[1].
Which region dominates the plasma-derived therapy market?
North America holds over 52.2% of the business share in the plasma-derived therapy market[1].
What are the main drivers of the plasma-derived therapy market growth?
The main drivers include the increasing prevalence of rare diseases, an aging population, and new drug approvals[1][2][4].
How do plasma-derived therapies impact healthcare costs?
Plasma-derived therapies can save healthcare costs by $60,000 per patient annually compared to alternative treatments[2].
What are the challenges facing the plasma-derived therapy market?
Supply and demand imbalances, the need for expanded plasma collection infrastructure, and securing financing for new fractionation plants are significant challenges[2][4].
